BACKGROUND: Left ventricular hypertrophy is common and is associated with cardiovascular events and death among patients with known chronic kidney disease. However, the link between reduced glomerular filtration rate (GFR) and left ventricular mass index (LVMI) remains poorly explored among young and middle-aged adults with preserved kidney function. In this study, we examined the association of cystatin C-based estimated GFR (eGFRcys) and rapid decline in eGFR with subsequent LVMI. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: We included 2,410 participants from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort with eGFRcys > 60mL/min/1.73m(2) at year 15 and who had an echocardiogram obtained at year 25. PREDICTOR: eGFRcys at year 15 and rapid decline in eGFRcys (defined as >3% per year over 5 years from years 15 to 20). OUTCOME: LVMI measured at year 25. MEASUREMENTS: We adjusted for age, sex, race, diabetes, body mass index, low- and high-density lipoprotein cholesterol levels, cumulative systolic blood pressure, and albuminuria. RESULTS: Mean age was 40±4 (SD) years, 58% were women, and 43% were black. After 10 years of follow-up, mean LVMI was 39.6±13.4g/m(2.7). Compared with eGFRcys > 90mL/min/1.73m(2) (n = 2,228), eGFRcys of 60 to 75mL/min/1.73m(2) (n = 29) was associated with 5.63 (95% CI, 0.90-10.36) g/m(2.7) greater LVMI (P = 0.02), but there was no association of eGFRcys of 76 to 90mL/min/1.73m(2) (n = 153) with LVMI after adjustment for confounders. Rapid decline in eGFRcys was associated with higher LVMI compared with participants without a rapid eGFRcys decline (β coefficient, 1.48; 95% CI, 0.11-2.83; P = 0.03) after adjustment for confounders. LIMITATIONS: There were a limited number of participants with eGFRcys of 60 to 90mL/min/1.73m(2). CONCLUSIONS: Among young and middle-aged adults with preserved kidney function, eGFRcys of 60 to 75mL/min/1.73m(2) and rapid decline in eGFRcys were significantly associated with subsequently higher LVMI. Further studies are needed to understand the mechanisms that contribute to elevated LVMI in this range of eGFRcys.
BACKGROUND: Left ventricular hypertrophy is common and is associated with cardiovascular events and death among patients with known chronic kidney disease. However, the link between reduced glomerular filtration rate (GFR) and left ventricular mass index (LVMI) remains poorly explored among young and middle-aged adults with preserved kidney function. In this study, we examined the association of cystatin C-based estimated GFR (eGFRcys) and rapid decline in eGFR with subsequent LVMI. STUDY DESIGN: Observational study. SETTING & PARTICIPANTS: We included 2,410 participants from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort with eGFRcys > 60mL/min/1.73m(2) at year 15 and who had an echocardiogram obtained at year 25. PREDICTOR: eGFRcys at year 15 and rapid decline in eGFRcys (defined as >3% per year over 5 years from years 15 to 20). OUTCOME: LVMI measured at year 25. MEASUREMENTS: We adjusted for age, sex, race, diabetes, body mass index, low- and high-density lipoprotein cholesterol levels, cumulative systolic blood pressure, and albuminuria. RESULTS: Mean age was 40±4 (SD) years, 58% were women, and 43% were black. After 10 years of follow-up, mean LVMI was 39.6±13.4g/m(2.7). Compared with eGFRcys > 90mL/min/1.73m(2) (n = 2,228), eGFRcys of 60 to 75mL/min/1.73m(2) (n = 29) was associated with 5.63 (95% CI, 0.90-10.36) g/m(2.7) greater LVMI (P = 0.02), but there was no association of eGFRcys of 76 to 90mL/min/1.73m(2) (n = 153) with LVMI after adjustment for confounders. Rapid decline in eGFRcys was associated with higher LVMI compared with participants without a rapid eGFRcys decline (β coefficient, 1.48; 95% CI, 0.11-2.83; P = 0.03) after adjustment for confounders. LIMITATIONS: There were a limited number of participants with eGFRcys of 60 to 90mL/min/1.73m(2). CONCLUSIONS: Among young and middle-aged adults with preserved kidney function, eGFRcys of 60 to 75mL/min/1.73m(2) and rapid decline in eGFRcys were significantly associated with subsequently higher LVMI. Further studies are needed to understand the mechanisms that contribute to elevated LVMI in this range of eGFRcys.
Authors: Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf Journal: J Clin Invest Date: 2011-10-10 Impact factor: 14.808
Authors: Shih-Han S Huang; Jennifer J Macnab; Jessica M Sontrop; Guido Filler; Kerri Gallo; Robert M Lindsay; William F Clark Journal: Transl Res Date: 2011-02-05 Impact factor: 7.012
Authors: Adriana J van Ballegooijen; Marjolein Visser; Bryan Kestenbaum; David S Siscovick; Ian H de Boer; John S Gottdiener; Christopher R deFilippi; Ingeborg A Brouwer Journal: Am J Cardiol Date: 2012-11-17 Impact factor: 2.778
Authors: Meyeon Park; Chi-yuan Hsu; Yongmei Li; Rakesh K Mishra; Martin Keane; Sylvia E Rosas; Daniel Dries; Dawei Xie; Jing Chen; Jiang He; Amanda Anderson; Alan S Go; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2012-08-30 Impact factor: 10.121
Authors: Lesley A Inker; John Eckfeldt; Andrew S Levey; Catherine Leiendecker-Foster; Gregory Rynders; Jane Manzi; Salman Waheed; Josef Coresh Journal: Am J Kidney Dis Date: 2011-08-19 Impact factor: 8.860
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: A J van Ballegooijen; M Visser; M F Cotch; A E Arai; M Garcia; T B Harris; L J Launer; G Eiríksdóttir; V Gudnason; I A Brouwer Journal: J Clin Endocrinol Metab Date: 2013-04-12 Impact factor: 5.958
Authors: Carmen A Peralta; Eric Vittinghoff; Nisha Bansal; David Jacobs; Paul Muntner; Bryan Kestenbaum; Cora Lewis; David Siscovick; Holly Kramer; Michael Shlipak; Kirsten Bibbins-Domingo Journal: Am J Kidney Dis Date: 2013-03-07 Impact factor: 8.860
Authors: Kalani T Yamamoto; Cassianne Robinson-Cohen; Marcia C de Oliveira; Alina Kostina; Jennifer A Nettleton; Joachim H Ix; Ha Nguyen; John Eng; Joao A C Lima; David S Siscovick; Noel S Weiss; Bryan Kestenbaum Journal: Kidney Int Date: 2013-01-02 Impact factor: 10.612
Authors: Casey M Rebholz; Adrienne Tin; Yang Liu; Marie Fanelli Kuczmarski; Michele K Evans; Alan B Zonderman; Deidra C Crews Journal: Am J Nephrol Date: 2016-10-22 Impact factor: 3.754
Authors: Maciej Banach; Wilbert S Aronow; Maria-Corina Serban; Jacek Rysz; Luminita Voroneanu; Adrian Covic Journal: Lipids Health Dis Date: 2015-12-30 Impact factor: 3.876
Authors: Donald M Lloyd-Jones; Cora E Lewis; Pamela J Schreiner; James M Shikany; Stephen Sidney; Jared P Reis Journal: J Am Coll Cardiol Date: 2021-07-20 Impact factor: 27.203
Authors: Huanwen Chen; Terry Watnick; Susie N Hong; Barry Daly; Yongfang Li; Stephen L Seliger Journal: BMC Nephrol Date: 2019-10-25 Impact factor: 2.388